Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E plus B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance) Kulke, M. H., Niedzwiecki, D., Foster, N. R., Fruth, B., Kunz, P. L., Kennecke, H. F., Wolin, E. M., Venook, A. P. AMER SOC CLINICAL ONCOLOGY. 2015
View details for DOI 10.1200/jco.2015.33.15_suppl.4005
View details for Web of Science ID 000358036900844